Transcription

1 10 4 TH TH WORKSHOP INTERNATIONAL WORKSHOP ON CO-INFECTION NEW ANTIVIRALS IN CLINICAL PRACTICE HIV & HEPATITIS PARIS, FRANCE JUNE DECEMBER EVALUATION REPORT

2 EXECUTIVE SUMMARY The 4th International Workshop on HCV Therapy Advances - took place on 12 & 13 December 2014 in Paris, France. A total of 110 delegates coming from 20 different countries participated in the event. There was an increase of almost 10 % in delegate numbers. 93% of all participants indicated themselves as first time participants, 91% of the delegates indicated to plan to attend this workshop again next year. See the following chart for the professional background of all participants: Nurse 13% Other 15% Clinician 34% Community rep 10% Researcher 28% 67% of the delegates indicated to change their daily practice after attending the workshop and after day 2 64% indicated that their medical and practical knowledge was enhanced. A total of 90% of the delegates agreed that they would have insight in the various aspects of the different drug classes affecting the regimen choice. Also the workshop added to the knowledge on the patient populations appropriate for shorter duration therapy (97% agreed) and created understanding on the impact on SVR of shorter duration therapy by treatment regimen (97% agreed). The program provided an excellent format including, invited speakers and panel debates. The quality of the program was really good, especially the debate stood out with a 100% score for Excellent/Good. The content and the presentation of all speakers were very well perceived by the audience as well. At average, for the invited speakes, 91% of the content of the letures was scored Excellent/Good and 89% of the presentations was scored Exellent/Good. The average score for all presentations is 9,0 points on a scale of 10. Regarding the logistics, the meeting was also very well perceived by all participating delegates. The location for the meeting was very well suitable (96% score for Excellent/Good) and the on-site staff was consifred to be professional and helpful (97% score for Excellent/Good). Most people were attracted to attend the meeting by word of mouth (54%) and 34% were influenced to attend the meeting by the newsletter update sent through the meeting secretariat. The Program Committee and the Organizing Secretariat are pleased with the evaluation results of the 4th International Workshop on HCV Therapy Advances - and are looking forward to an even more successful edition in 2015! The results presented in this evaluation report were based on 119 completed evaluation forms. EVALUATION REPORT 4 th HCV Theraphy Advances - 2

3 CONTENT Executive Summary... 2 Introduction... 4 Background... 4 Meeting Objectives... 4 Format... 4 Unique Meeting Features... 4 Target Audience... 5 Learning Objectives... 5 Acknowledgements... 6 Organizing Committee... 7 Meeting demographics... 8 Number of Participants... 8 Professional Background... 8 Participants Feedback Friday 12 December... 9 Personal Benefits... 9 Content... 9 Lectures... 9 Saturday 13 December Personal Benefits Content Lectures General Learning Objectives Next Year Average Scores Participants Feedback Logistics Communication Publicity Metrics Pre-workshop Communication Post-workshop Communication Conclusion List of Participants EVALUATION REPORT 4 th HCV Theraphy Advances - 3

4 INTRODUCTION This is the evaluation report of the 4th International Workshop on HCV Therapy Advances -, held on 12 and 13 December 2014 in the Hotel Pullman Paris Tour Eifel (4*) in Paris, France. The Program Commitee and the Organizing Secretariat highly value the opinion of the participants in order to further improve the quality of the workshop. All participants were asked to complete an evaluation form for each workshop day. We thank all participants for sharing their opinion. The general opinion of the audience is presented in this evaluation report. Based on the feedback provided we aim to continuing improving the quality of this workshop. BACKGROUND The entrance of HCV direct acting antivirals into routine clinical practices provides a great opportunity for improved care, but at the same time, substantial challenges for the treating physician. The Workshop on HCV Therapy Advances has been developed to educate treating physicians and researchers, to discuss the latest developments in the field of hepatitis treatment and the promising new treatment possibilities of new direct antivirals that are becoming available. The meeting is intended as a platform for sharing data and discussing the clinical application of these new antivirals. The conference presentations and case discussions presented by international recognized experts in the field are focused on the translation of the latest scientific data and availability of new drugs into daily clinical practice. MEETING OBJECTIVES The objective of this meeting is to create an interactive setting in which key opinion leaders present and discuss the latest scientific data on clinical management of hepatitis infected patients. FORMAT This 1,5 day international workshop consists of invited lectures and panel debates in which sufficient time is allocated for interactive discussion between the panel and the audience. UNIQUE MEETING FEATURES The workshop is a unique European platform for clinicians and other professionals working in the field of viral hepatitis, translating new data into new treatment strategies to further improve clinical care The workshop attracts different disciplines involved in the field of HCV therapy The workshop includes the latest data presented at EASL, APASL and AASLD The workshop stimulates European collaborations and networks The workshop stimulates updates on guidelines and encourages treatment efficiency EVALUATION REPORT 4 th HCV Theraphy Advances - 4

5 INTRODUCTION TARGET AUDIENCE Hepatologists Infectious disease doctors Gastroenterologists Other healthcare professionals involved in daily care of hepatitis patients Post-graduate students LEARNING OBJECTIVES Have an understanding of the basic concepts of HCV therapy. Be updated on the latest developments in the field of HCV antiviral research. Have an understanding of the challenges of HCV treatment in different patient populations. Have an overview of the advantages and possibilities of Have an understanding of the basic concepts of HCV therapy. Be updated on the latest developments in the field of HCV antiviral research. Have an understanding of the challenges of HCV treatment in different patient populations. Have an overview of the advantages and possibilities of new antivirals in HCV therapy. Know how to apply direct acting antivirals in clinical practice. EVALUATION REPORT 4 th HCV Theraphy Advances - 5

6 ACKNOWLEDGEMENTS The organizers acknowledge the contributions of our sponsors that have made the 4 TH WORKSHOP ON - NEW ANTIVIRALS IN CLINICAL PRACTICE possible: GOLD LEVEL SPONSORS PRINCIPAL SUPPORTER ENDORSEMENTS EVALUATION REPORT 4 th HCV Theraphy Advances - 6

7 ORGANIZING COMMITTEE CHARLES BOUCHER, MD, PHD Erasmus Medical Center Rotterdam, the Netherlands FRED POORDAD, MD Texas Liver Institute/ University of Texas Health Science Center Texas, USA STEFAN ZEUZEM, MD J.W. Goethe University Hospital Frankfurt, Germany EVALUATION REPORT 4 th HCV Theraphy Advances - 7

8 MEETING DEMOGRAPHICS NUMBER OF PARTICIPANTS A growth of attendance numbers was seen in delegates from 20 countries participated in the event. The largest group was from France (35). 86% of the participants indicated themselves as first time participants and 14% are returning participants. The geographical distribution of participants is as follows: Country Delegates Country Delegates Canada 2 the Netherlands 4 Denmark 3 Norway 1 Egypt 3 Poland 8 Finland 3 Portugal 1 France 35 Romania 2 Germany 2 Spain 3 Greece 1 Sweden 14 Israel 2 Turkey 1 Italy 2 United Kingdom 11 Lithuania 11 USA 4 PROFESSIONAL BACKGROUND Main activity: Mainly employed by: Nurse 13% Community rep 10% Other Other 15% University Clinician 22% 30% 34% Researcher 28% Industry marketing 13% Industry medical 12% Hospital 23% Area of expertise: Other 17% Hepatitis B 32% Hepatitis C 51% EVALUATION REPORT 4 th HCV Theraphy Advances - 8

9 PARTICIPANTS FEEDBACK 2014 FRIDAY 12 DECEMBER 2014, DAY 1 PERSONAL BENEFITS The content presented of this workshop day will improve my: Very much agree Agree Neutral Disagree Very much disagree Medical and/or Practical Knowledge 49% 34% 14% 0% 3% Care Attitudes 37% 30% 26% 7% 0% Procedural or Cognitive Skills 27% 27% 35% 8% 4% Practice Behavior 31% 31% 35% 4% 0% Patients Clinical Outcomes 31% 38% 27% 4% 0% CONTENT Agree Disagree Disagree The content of this day s program met my expectations 94% 3% 3% Sufficient time was allocated for discussion 83% 14% 3% The allocated time per presentation was sufficient 76% 12% 12% I perceived no commercial bias at this workshop day 90% LECTURES Session 1 Presented Data 2014 Pivotal New England Journal of Medicine Papers 2014 Phase 3 Trial Data S. Zeuzem, MD News from AASLD Nuke Regimens F. Poordad, MD News from AASLD Non Nuke Regimens M. Buti, MD, PhD Excellent Good Average Fair Poor Content 56% 37% 7% 0% 0% Presentation 58% 38% 4% 0% 0% Excellent Good Average Fair Poor Content 71% 24% 5% 0% 0% Presentation 68% 28% 4% 0% 0% Excellent Good Average Fair Poor Content 46% 39% 10% 5% 0% Presentation 40% 35% 13% 12% 0% EVALUATION REPORT 4 th HCV Theraphy Advances - 9

10 PARTICIPANTS FEEDBACK 2014 GILEAD - Satellite Symposium Presentations Excellent Good Average Fair Poor Content 63% 31% 6% 0% 0% Presentation 59% 35% 6% 0% 0% I will change my daily practice as a result of attending this Satellite Symposium Very much Agree Neutral Disagree Very much agree disagree 34% 29% 29% 4% 4% Session 2 Differential Benefits of DAA s in Different Patient Populations In Patients on a Waiting List for Liver Transplantation Excellent Good Average Fair Poor Content 36% 53% 11% 0% 0% The Data - R. Brown, MD, PhD Excellent Good Average Fair Poor Presentation 39% 50% 11% 0% 0% The Clinic - R. de Knegt, MD, PhD Excellent Good Average Fair Poor Presentation 49% 43% 8% 0% 0% In HIV - HCV Coinfected Patients Excellent Good Average Fair Poor Content 44% 33% 19% 3% 0% The Data - K. Lacombe, MD, PhD Excellent Good Average Fair Poor Presentation 39% 32% 24% 5% 0% The Clinic - S. Pol, MD, PhD Excellent Good Average Fair Poor Presentation 39% 32% 24% 5% 0% In HIV - HCV Coinfected Patients Excellent Good Average Fair Poor Content 65% 25% 10% 0% 0% The Data - G. Dusheiko, MD Excellent Good Average Fair Poor Presentation 65% 25% 10% 0% 0% The Clinic - M. Bourlière, MD Excellent Good Average Fair Poor Presentation 55% 30% 10% 5% 0% EVALUATION REPORT 4 th HCV Theraphy Advances - 10

11 PARTICIPANTS FEEDBACK 2014 SATURDAY 13 DECEMBER, DAY 2 PERSONAL BENEFITS The content presented at this workshop day will improve my: Very much agree Agree Neutral Disagree Very much disagree Medical and/or Practical Knowledge 64% 29% 7% 0% 0% Care Attitudes 43% 36% 18% 4% 0% Procedural or Cognitive Skills 44% 40% 12% 4% 0% Practice Behavior 32% 48% 16% 4% 0% Patients Clinical Outcomes 44% 40% 16% 0% 0% CONTENT Agree Neutral Disagree The content of the meeting met my expectations 94% 6% 0% Sufficient time allocated for discussion during the meeting 97% 3% 0% The allocated time per presentation was sufficient 97% 0% 3% I perceived no commercial bias at this workshop day 88% LECTURES I gained new insights from the following invited lectures and discussions (in chronological order) Session 3 Next Steps 2015 and Beyond What is the Optimized Treatment Duration? To Over treat versus Undertreat N. Reau, MD Comparing the Different Guidelines (WHO/EASL/AASLD) F. Poordad, MD Excellent Good Average Fair Poor Content 57% 37% 6% 0% 0% Presentation 57% 40% 3% 0% 0% Excellent Good Average Fair Poor Content 60% 37% 3% 0% 0% Presentation 63% 37% 0% 0% 0% Panel Discussion Country Specific Consideration of the Guidelines Excellent Good Average Fair Poor Content 70% 30% 0% 0% 0% EVALUATION REPORT 4 th HCV Theraphy Advances - 11

12 PARTICIPANTS FEEDBACK 2014 ABBVIE - Satellite Symposium Presentations Excellent Good Average Fair Poor Content 52% 39% 9% 0% 0% Presentation 55% 35% 10% 0% 0% My daily practice will be enhanced after attending this Satellite Symposium Very much Agree Neutral Disagree Very much agree disagree 33% 50% 13% 4% 0% Session 4 Eradication What are the Critical Steps Needed for Global HCV Eradication H. Wedemeyer, MD Excellent Good Average Fair Poor Content 56% 41% 3% 0% 0% Presentation 62% 38% 0% 0% 0% EVALUATION REPORT 4 th HCV Theraphy Advances - 12

13 PARTICIPANTS FEEDBACK 2014 GENERAL LEARNING OBJECTIVES Were the following learning objectives met? After attending this event, the participant will demonstrate the ability to: Agree Neutral Disagree Have insight in the various aspects of the different drug classes affecting the regimen choice 90% 7% 3% Understand the efficacy and safety differences between nucleoside agents in HCV 84% 13% 3% Is aware of the similarities and differences in various HCV guidelines 94% 6% 0% Have knowledge on the patient populations appropriate for shorter duration therapy Understand the impact on SVR of shorter duration therapy by treatment regimen Understand the current and upcoming treatment options for hepatitis C in advanced disease and liver transplantation Have knowledge on the potential drug drug interaction in co-infected patients 97% 3% 0% 97% 3% 0% 86% 13% 0% 70% 27% 3% NEXT YEAR I will change my daily practice after attending this workshop 67% I plan to attend this workshop again next year 91% AVERAGE SCORES PARTICIPANTS FEEDBACK Percentage of scores scored Excellent/Good Content Presentation Invited speakers 91% 89% Debates 100% - EVALUATION REPORT 4 th HCV Theraphy Advances - 13

14 PARTICIPANTS FEEDBACK LOGISTICS Excellent Good Average Fair Poor Location was suitable for this meeting 63% 33% 4% 0% 0% Location was easy to reach 60% 35% 5% 0% 0% Food & beverages were good and sufficient 56% 26% 13% 5% 0% Audio-visual equipment was good and sufficient 48% 38% 14% 0% 0% On-site staff was professional and helpful 55% 43% 3% 0% 0% COMMUNICATION Excellent Good Average Fair Poor The information received through the newsletters was sufficient The information received through the logistical letter was useful I perceived the information at the Virology Education website as useful 33% 59% 4% 4% 0% 34% 58% 8% 0% 0% 46% 50% 4% 0% 0% PUBLICITY Influenced to attend this meeting by: Colleague / word of mouth 45% VE announcement 34% Invite from industry 14% VE website 3% Other conference agenda 2% Internet search 2% EVALUATION REPORT 4 th HCV Theraphy Advances - 14

15 METRICS 2014 PRE-WORKSHOP COMMUNICATION Frequency/Number Publicity through electronic newsletter Flyers at other meetings Endorsement by societies Publicity on conference websites Invitations from industry Publicity through associations and other organizations 5 electronic newsletters have been sent to an international group of recipients. 1 electronic newsletter has been dedicated to attract Dutch participants. The meeting flyer has been distributed at the EASL The Liver Meeting 2014 and at AASLD The meeting is endorsed by Société Francaise de Lutte Contre Le SIDA (SFLS) and ANRS The website has been promoted at multiple international meeting websites. Participants to the meeting were brought by Gilead, AbbVie, BMS and Roche The meeting has been promoted on the websites of the endorsing societies. POST-WORKSHOP COMMUNICATION Webcast/On-line education Publication of presentation slides online Post Conference Newsletter A webcast of the invited lectures has been made available online for educational purposes at The slides of the presentations have been made available online at infectiousdiseasesonline.com/4th-hcv-therapy-advpresentations. A Post Conference Newsletter with a link to the webcast and presentation slides has been sent to the participants of this and previous years workshops. EVALUATION REPORT 4 th HCV Theraphy Advances - 15

16 CONCLUSION The Program Committee is pleased with the results of the 4 th Workshop on HCV Therapy Advances. Participants were satisfied with the scientific content of the workshop as well as with the logistics and the format of the program. The Program Committee looks forward to organizing the 5 th edition of the workshop and to welcoming returning and new participants in December 2015 in Amsterdam, the Netherlands. EVALUATION REPORT 4 th HCV Theraphy Advances - 16

17 LIST OF PARTICIPANTS Last name, name Affiliation Country A Allam, Setty National Agency for Aids Research (ANRS) France Alsiö, Åsa AbbVie Sweden Awad, Tahany AbbVie Denmark B Barker, Gemma Gilead United Kingdom Bergkvist, Pär Inge Lasarettet Helsingborg Sweden Blondon, Hugues Hôpital André Mignot France Boman, Eva-Marie SÄS Borås Sweden Bottero, Julie Hôpital Saint Antoine Paris France Boucher, Charles Erasmus Medical Center The Netherlands Bourlière, Marc Hopital Saint Joseph France Brown, Robert Columbia University Medical Center USA Burgess, Wendy Elements Communications United Kingdom Buti, Maria Hospital Valle Hebron Spain C Caretu, Adrian AbbVie France Carr, Val Gilead United Kingdom Charafeddine, Mariem AbbVie France Cheddani, Halima Hôpital Tenon France Coelingh Bennink, David AbbVie France Coull, Jason Gilead United Kingdom D De Knegt, Robert Erasmus Medical Center The Netherlands De Roij, Caroline AbbVie The Netherlands Delaage, Pierre Henri AbbVie France Doumet, Sylva Hopital Lucie Aubrac VSG France Duchesne, Léa St. Antoine Hospital of Paris France Dusheiko, Geoffrey Royal Free Hospital United Kingdom Edvardsen, Hege AbbVie Norway Elefsiniotis, Ioannis University of Athens Greece Everson, Gregory University of Colorado Denver USA F Ferrinho, Diogo Gilead United Kingdom Foster, Graham Queen Mary, University of London United Kingdom Fourati, Slim Hôpital Henri Mondor, Université Paris XII France Francisco, Sousa AbbVie Portugal Friis-Liby, Ingalill Sahlgrenska University Hospital Sweden G Gainaru, Cristian Bristol Myers Squibb Romania Gallinaro, Valentina Abbvie Italy EVALUATION REPORT 4 th HCV Theraphy Advances - 17

18 Last name, name Affiliation Country Griolet, Christophe Gilead United Kingdom Grimes-Crompton, Chris Gilead United Kingdom Last name, First name Institute Country H Hanvesakul, Rajesh Gilead United Kingdom Hertz, Lital Abbvie Israel Hézode, Christophe Hôpital Henri Mondor, Université Paris XII France I Ignacio de los Santos Gil J Spain Jakutiene, Jolita Vilnius University Hospital Santariskiu Klinikos Lithuania Jancoriene, Ligita The Hospital of Infectious Diseases and Tuberculosis Lithuania K Kalinowska-Nowak, Anna Oddzial Kliniczny Klinik Gastroenterologii i Hepatologii oraz Chorob Zakaznych Poland Kishta, Sara National Research Center Egypt Klimowicz, Katarzyna Centralny Szpital Kliniczny MSW, Oddzial Chorob Wewnetrznych i Hepatologii Poland Korczynska, Aleksandra Wojewodzki Szpital Zakazny w Warszawie Poland Kovamees, Jan AbbVie Sweden Koziel, Katarzyna L Oddzial Chorob Zakaznych, Szpital Wojewodzki w Zielonej Gorze Poland Laaksonen, Juha-Matti Kanta-Häme Central Hospital Finland Lacombe, Karine Hôpital Saint Antoine Paris France Lannergård, Anders AbbVie Sweden Lelouch, Stéphane Centre Hospitalier De Longjumeau France Lopes de Sousa, Francisco AbbVie Portugal Lurquin, David Gilead France M Mathiex Fortunet, Hélène Hôpital Saint Antoine Paris France Matukiewicz, Marek Oddzial Chorob Zakaznych, Szpital Wojewodzki w Zielonej Gorze Poland Mertens, Michael Gilead United Kingdom Mihai, Camelia Bristol Myers Squibb Romania Mostafa, Dina The National Research Center Egypt N Nguyen, Tien AbbVie Sweden Nicolson, Iain Medical Expressions United Kingdom O Oncu, Serkan AydÐn Adnan Menderes University Turkey Ouda, Derradji Chu De Bicetre France EVALUATION REPORT 4 th HCV Theraphy Advances - 18

19 Last name, name Affiliation Country P Pais, Raluca Hôpital La Pitié Salpétrière France Pangerl, Andreas Abbvie Biopharmaceuticals France Parlier, David France Pauwels, Arnaud CH Emmanuel Rain France Perttilä, Julia AbbVie Finland Petrauskas, Dalius Petrenkiene, Vitalija Hospital of Lithuanian University of Health Sciences Kauno Klinikos Hospital of Lithuanian University of Health Sciences Kauno Klinikos Lithuania Lithuania Petruliene, Vilija Kaunas Clinical Hospital Lithuania Pol, Stanislas University of Paris V France Poordad, Fred The Texas Liver Institute / UT Health Science Center, San Antonio Popa, Ingrid Hia Percy France Pospai, Dan Hôpital Bichat-Claude Bernard France Posserud, Iris Anette Sahlgrenska University Hospital Sweden Prydz, Andreas AbbVie Sweden R Reau, Nancy University of Chicago USA Robinson, Chris Gilead United Kingdom Rohel, Alexandra ANRS, The French National Agency for Research on AIDS and Viral Hepatitis USA France Roulot Marullo, Dominique Hôpital Avicenne-Université Paris 13 France Rousseau, Annie Hopital du Haut Richelieu Canada S Salem, Eman The National Research Center Egypt Salminen, Kimmo Turku Universiry Central Hospital Finland Schlichting, Poul Herlev Hospital Denmark Searle, Karen Elements Communications United Kingdom Shlomai, Amir Rabin Medical Center Israel Silén, Åsa Sahlgrenska University Hospital Sweden Simulionis, Giedrius Klaipeda Seamen s Hospital Lithuania Skalshøj Kjær, Mette Rigshospitalet Denmark Smiatacz, Tomasz Klinika Chorob Zakaznych GUMED Poland Sobesky, Rodolphe Hopital Marc Jacquet France Soderholm, Jonas AbbVie Sweden Souri, Pega AbbVie Sweden Speiciene, Danute Marija Vilnius University Hospital Santariskiu Klinikos Lithuania Sultanik, Philippe Hôpital Cochin France Sumskiene, Jolanta Hospital of Lithuanian University of Health Sciences Kauno Klinikos Lithuania EVALUATION REPORT 4 th HCV Theraphy Advances - 19

20 Last name, name Affiliation Country T Teicher, Elina Chu De Bicetre France Testa, Angela AbbVie Italy Thibault, Vincent Hôpital La Pitié Salpétrière France Titova, Birute Vilnius University Hospital Santariskiu Klinikos Lithuania Tran, Hanh-Khiem Hôpital Charles Lemoyne Canada Tsakiris, Laurent Hopital Marc Jacquet France V Vesslén, Lars Birger Gävle sjukhus Sweden Vilkiene, Egle Roche Lithuania Lithuania Vivona-Clerc, Veronique Abbvie Biopharmaceuticals France Voinic, Alina The Hospital of Infectious Diseases and Tuberculosis Lithuania W Wallér, Jon Emanuel Edman SÄS Borås Sweden Wedemeyer, Heiner Medical School Hannover Germany Wrodycki, Witold Wojewodzki Specjalistyczny Szpital im. Dr W. Bieganskiego w Lodzi Z Poland Zeuzem, Stefan JW Goethe Univ. Hospital Germany EVALUATION REPORT 4 th HCV Theraphy Advances - 20

21 EVALUATION REPORT 4 th HCV Theraphy Advances - 21